Skip to content
Peptide research

Catestatin

Also known as CST · Chromogranin A Fragment
Category
Cardiovascular
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A chromogranin A fragment from nerve endings and adrenal glands, marketed for blood pressure, heart, and gut support. Evidence is mostly animal and mechanistic; in humans it is studied mainly as a heart failure biomarker, while hypertension and colitis claims stay low confidence. Therapeutic safety remains unestablished, and suppressing adrenaline raises concern for hypotension and allergy. Not approved, and available products are unregulated.

Read Full record

Studied uses & evidence

Studied uses(7)

  • Blood pressure regulation and antihypertensive effects

    Low

    Animal evidence and limited human vascular experiments; antihypertensive treatment benefit remains unproven.

  • Cardioprotection against ischemia-reperfusion injury

    Low

    Reduced infarct size in rodent heart studies via defined signaling pathways; no human data exist.

  • Improved insulin sensitivity and metabolic function

    Low

    Improved insulin sensitivity in mouse and rat studies only; human data are limited to associations.

Evidence limits

Evidence Level
Preclinical

Therapeutic evidence remains predominantly preclinical, from in vitro cell culture and in vivo animal (primarily mouse) studies. Human research includes observational biomarker studies, population genetics, and controlled local-infusion experiments. The CATSTAT-HF study (NCT03389386), the largest dedicated clinical study, measured endogenous catestatin in 90 acutely decompensated heart failure patients. Population genetics studies in Indian cohorts (approximately 4,000 subjects) linked catestatin variants to hypertension risk. These findings do not establish clinical treatment benefit. The preclinical evidence across cardiovascular, metabolic, inflammatory, and antimicrobial domains is consistent and compelling, but clinical translation has not yet begun.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Severe hypotension

    High

    Catestatin inhibits catecholamine release and causes vasodilation. May dangerously lower BP in hypotensive patients.

  • Pheochromocytoma or catecholamine-secreting tumors

    Moderate

    Catestatin modulates catecholamine dynamics. Unpredictable effects on catecholamine-secreting tumors.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data. Affects catecholamine and cardiovascular regulation.

Risk summary(7)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Therapeutic safety remains unestablished

    High
  • Hypotension and cardiovascular depression

    Moderate
  • Histamine release and allergic-type reactions

    Moderate
  • Immune modulation with unpredictable consequences

    Moderate
  • Sympathetic rebound or autonomic instability

    Theoretical
  • Research-grade product quality and contamination

    High
  • Variant-specific differential effects

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.